Trial Profile

A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2025 According to an Oculis Pharma media release, company announced that company will give update from this study innovative at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting.
01 Sep 2025 According to an Oculis Pharma media release, expanded data analyses from Stage I from this trial will be presented at at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress.
21 Aug 2025 According to an Oculis Pharma media release, Topline results from both trials are expected in Q2 2026 with NDA submission planned for 2H 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com